癌症和血栓性疾病

Cancer and Thromboembolic Disease

血栓形成是癌症患者的一个常见并发症,在癌症患者尸检中发现其患血栓性疾病的比率非常高。同时,在患静脉血栓的人群中肿瘤的发病率明显增加。肿瘤和宿主之间复杂的相互作用过程诸如血小板增多,纤维蛋白原激活增强及纤维蛋白溶解的抑制,肿瘤细胞释放组织因子(TF)和癌症促凝物(CP),机体炎性反应以及手术放化疗对血管内皮的损伤等综合因素导致了患者高凝状态的发生。对癌症伴发的静脉栓塞(VET)的治疗通常首选低分子量肝素(LMWH)及华法令。

Thrombosis is a frequent complication of cancer. In the patients died of cancer , autopsy showed that the mobidity of thromboembolic disease was very high. Meanwhile, the tumor mobidity was higher in the population with venous thrombosis than in the common population. The complex interaction between tumor and the host induced the hypercoagulable state including thrombocytoais, promotion of fibrinogen activation and inhibition of fibrin. olysis, tissue factor（TF） and cancer procoagulant（CP） secreted by tumor cells, host inflammatory and endotbelium damaged by surgery and ehemoradiotherapy. LMWH and Warfarin had become the first choice of anticoagulants in treating VET witb cancer.